206 related articles for article (PubMed ID: 25091467)
1. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.
Fichter CD; Gudernatsch V; Przypadlo CM; Follo M; Schmidt G; Werner M; Lassmann S
J Mol Med (Berl); 2014 Nov; 92(11):1209-23. PubMed ID: 25091467
[TBL] [Abstract][Full Text] [Related]
2. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
3. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas.
Timme S; Ihde S; Fichter CD; Waehle V; Bogatyreva L; Atanasov K; Kohler I; Schöpflin A; Geddert H; Faller G; Klimstra D; Tang L; Reinheckel T; Hauschke D; Busch H; Boerries M; Werner M; Lassmann S
Oncogene; 2014 Jun; 33(25):3256-66. PubMed ID: 23912451
[TBL] [Abstract][Full Text] [Related]
4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells.
Fichter CD; Herz C; Münch C; Opitz OG; Werner M; Lassmann S
BMC Cell Biol; 2011 Apr; 12():13. PubMed ID: 21470402
[TBL] [Abstract][Full Text] [Related]
7. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
8. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
[TBL] [Abstract][Full Text] [Related]
9. Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Zhang J; Gelman IH; Katsuta E; Liang Y; Wang X; Li J; Qu J; Yan L; Takabe K; Hochwald SN
Cell Mol Gastroenterol Hepatol; 2019; 8(1):37-60. PubMed ID: 30836148
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma.
Chai AW; Cheung AK; Dai W; Ko JM; Ip JC; Chan KW; Kwong DL; Ng WT; Lee AW; Ngan RK; Yau CC; Tung SY; Lee VH; Lam AK; Pillai S; Law S; Lung ML
Oncotarget; 2016 Nov; 7(48):78859-78871. PubMed ID: 27793011
[TBL] [Abstract][Full Text] [Related]
11. The Rho GTPase RhoE exerts tumor-suppressing effects in human esophageal squamous cell carcinoma via negatively regulating epidermal growth factor receptor.
Wang H; Wang Y; Liang B; He F; Li Y; Che J; Li X; Zhao H; Shi G
J Cancer Res Ther; 2016 Oct; 12(Supplement):60-63. PubMed ID: 27721256
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
13. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
14. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
Kang J; Guo Z; Zhang H; Guo R; Zhu X; Guo X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142299
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
[TBL] [Abstract][Full Text] [Related]
16. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
18. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells.
Hoque M; Elmaghrabi YA; Köse M; Beevi SS; Jose J; Meneses-Salas E; Blanco-Muñoz P; Conway JRW; Swarbrick A; Timpson P; Tebar F; Enrich C; Rentero C; Grewal T
FEBS J; 2020 Jul; 287(14):2961-2978. PubMed ID: 31869496
[TBL] [Abstract][Full Text] [Related]
19. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
20. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
